Capillary Bed Bioreactor: Improved Estimation Of Dermal Bioavailability

从历史上看，动物试验一直被用来支持与化妆品成分相关的风险评估。然而，近年来，为支持新化妆品的风险评估而进行的动物试验水平不断降低，并朝着对人类毒理学的机械性理解(纳入基于暴露的风险评估)的方向发展。因此，开发用于预测新化学品安全性的非动物模型是必要的，以产生数据，从而增加对体内情景预测的信心。联合利华用于评估皮肤生物利用度的模型利用扩散池中的皮肤(来自选择性整形手术)，并随着时间的推移监测测试项目在皮肤中的渗透情况。虽然这已被证明是一个合适的模型，但关于通过真皮毛细血管清除化学物质的情况却知之甚少。拟议的毛细管床生物反应器(CBB)通过以中空纤维膜的形式提供假性血管床，更好地复制了皮肤及其血液供应的体内环境。

Historically, animal testing has been used to support risk assessment related to cosmetic ingredients. However, in recent years, there has been a continuous drive to reduce the level of animal testing undertaken to support risk assessments for new cosmetic products, and a move towards a mechanistic understanding of human toxicology (incorporating exposure-based risk assessment). Consequently, the development of non-animal models for predicting the safety of new chemicals is necessary to generate data leading to increased confidence in predictions of in vivo scenarios. The model used by Unilever to assess dermal bioavailability utilises skin (from elective cosmetic surgery procedures) in diffusion cells, and the permeation of a test item through the skin is monitored over time. While this has proved to be an adequate model, little is known regarding chemical clearance via dermal capillaries. The proposed capillary bed bioreactor (CBB) better replicates the in vivo environment of the skin and its blood supply by providing a bed of pseudovascularisation in the form of hollow fibre membranes.